About 61% of patients with stage I or II dMMR colon cancer achieved a pathologic complete response after a single cycle of neoadjuvant pembrolizumab, new data revealed.
Armando, a 71-year-old with an active lifestyle, was midway through a round of golf when a strange sensation crept into his ...
The addition of lenvatinib and pembrolizumab to chemotherapy did not extend OS for certain patients with advanced ...
The company announced interim data showing strong systemic responses in its safety and efficacy study combining Alpha DaRT treatment with ...
3d
(RTTNews) - Bicara Therapeutics Inc. (BCAX), Monday announced the results from the Phase 1/1b dose expansion cohort, evaluating the combination of ficerafusp alfa with pembrolizumab in patients with ...
The phase 3 LEAP-015 trial evaluated the efficacy and safety of pembrolizumab with lenvatinib in patients with advanced/metastatic gastroesophageal cancer.
Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced a significant milestone: ...
( MENAFN - Investor Ideas) Investorideas ( ), a go-to platform for big investing ideas for stock traders, including biotech and medical tech Stocks reports on trading and news for Aethlon Medical, Inc ...
Rakuten Medical initiates global phase 3 trial of ASP-1929 photoimmunotherapy in combo with pembrolizumab to treat recurrent head and neck cancer: United States Saturday, January ...
Aethlon Medical, Inc. (Nasdaq: AEMD ), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious ...
Neoadjuvant Keytruda for patients with deficient DNA mismatch repair colon cancer resulted in a pathological complete ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback